Cidara Therapeutics, Inc. (CDTX) Stock Analysis

Cidara Therapeutics, Inc. (CDTX) Healthcare & Pipeline Overview

Cidara Therapeutics, Inc. is a biotechnology firm specializing in the discovery and development of anti-infective therapies. Their primary focus is rezafungin acetate, a novel antifungal, and the Cloudbreak platform targeting viral infections. The company addresses critical unmet needs in infectious disease treatment and prevention.

What Is the Investment Thesis for CDTX?

Cidara Therapeutics, Inc. presents a focused investment opportunity within the biotechnology sector, driven primarily by the potential of rezafungin acetate and the Cloudbreak platform. Rezafungin addresses a critical need for effective treatments against invasive fungal infections, a market with high mortality rates. Successful commercialization of rezafungin could drive significant revenue growth. The Cloudbreak platform offers additional upside through its application to various viral infections, including influenza and COVID-19. Key risks include clinical trial outcomes, regulatory approvals, and competition from existing antifungals. With a market cap of $5.61B and a beta of 1.53, Cidara exhibits moderate volatility. The company's success hinges on the clinical and commercial execution of its pipeline assets.

Based on FMP financials and quantitative analysis

CDTX Key Highlights

Cidara Therapeutics is focused on developing long-acting anti-infectives, addressing critical needs in infectious disease treatment.

• Rezafungin acetate, the lead product candidate, targets invasive fungal infections with high mortality rates.
• The Cloudbreak platform is designed to create conjugates for the prevention and treatment of viral infections.
• Cidara Therapeutics was incorporated in 2012 and is based in San Diego, California.
• The company's focus on long-acting therapeutics aims to improve patient outcomes through sustained drug exposure.

Who Are CDTX's Competitors?

CDTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CDTX's Key Strengths?

Novel anti-infective therapies targeting unmet medical needs.

• Proprietary Cloudbreak platform for viral infections.
• Lead product candidate, rezafungin acetate, with promising clinical data.
• Experienced management team with expertise in drug development.

What Are CDTX's Weaknesses?

Reliance on successful clinical trial outcomes and regulatory approvals.

• Limited commercial infrastructure compared to larger pharmaceutical companies.
• High cash burn rate associated with drug development.
• Competition from established anti-infective therapies.

What Could Drive CDTX Stock Higher?

Potential FDA approval and commercial launch of rezafungin acetate.

• Clinical trial results from Cloudbreak platform programs.
• Strategic partnerships and collaborations to expand product pipeline.
• Expansion into new geographic markets.

What Are the Key Risks for CDTX?

Negative return on equity (-60.1%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Unfavorable clinical trial results for rezafungin acetate or Cloudbreak programs.
• Regulatory setbacks or delays in obtaining FDA approval.
• Competition from established anti-infective therapies.
• Dependence on successful commercialization of rezafungin acetate.
• Changes in healthcare reimbursement policies affecting pricing and market access.

What Are the Growth Opportunities for CDTX?

• Rezafungin Commercialization: The successful commercialization of rezafungin acetate represents a significant growth opportunity for Cidara. The market for antifungals is substantial, driven by the increasing incidence of invasive fungal infections, particularly in immunocompromised patients. Securing regulatory approvals and establishing a strong market presence for rezafungin could generate substantial revenue streams. The timeline for this growth opportunity is dependent on regulatory milestones and market access strategies.
• Cloudbreak Platform Expansion: Cidara's Cloudbreak platform offers a versatile approach to developing conjugates for the prevention and treatment of various viral infections. Expanding the platform to address additional viral targets, such as RSV and HIV, could unlock new revenue streams and diversify the company's product portfolio. The market for antiviral therapies is substantial, driven by the ongoing threat of emerging viral pathogens. The timeline for this growth opportunity depends on preclinical and clinical development progress.
• Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of Cidara's product candidates. Collaborations could provide access to additional resources, expertise, and market reach. The pharmaceutical industry is characterized by a high degree of collaboration, with companies often partnering to share risks and rewards. The timeline for this growth opportunity is dependent on identifying suitable partners and negotiating favorable terms.
• Geographic Expansion: Expanding into new geographic markets, such as Europe and Asia, could drive additional growth for Cidara. The global market for anti-infective therapies is substantial, with significant unmet needs in many regions. Establishing a presence in these markets would require regulatory approvals and commercial infrastructure. The timeline for this growth opportunity depends on regulatory pathways and market entry strategies.
• Pipeline Development: Advancing additional product candidates through the clinical development pipeline represents a long-term growth opportunity for Cidara. Investing in research and development to identify and develop new anti-infective therapies could generate future revenue streams and enhance the company's competitive position. The biotechnology industry is characterized by a constant need for innovation, with companies continually seeking to develop new and improved treatments. The timeline for this growth opportunity depends on preclinical and clinical development progress.

What Are CDTX's Competitive Advantages?

• Proprietary Technology: The Cloudbreak platform provides a unique approach to developing conjugates for viral infections.
• Patent Protection: Patents on rezafungin acetate and other product candidates provide market exclusivity.
• Clinical Data: Positive clinical trial results can create a barrier to entry for competitors.
• Expertise: Specialized knowledge in anti-infective drug development and commercialization.

What Does CDTX Do?

Cidara Therapeutics, Inc., established in 2012 and based in San Diego, California, is a biotechnology company dedicated to the discovery, development, and commercialization of innovative, long-acting anti-infectives. Originally named K2 Therapeutics, the company rebranded in July 2014 to Cidara Therapeutics, Inc. The company's lead product candidate, rezafungin acetate, represents a novel approach in the echinocandin class of antifungals, designed to treat and prevent invasive fungal infections, including life-threatening conditions like candidemia and invasive candidiasis. These infections are associated with significant mortality rates, highlighting the critical need for effective treatments. Beyond rezafungin, Cidara is also advancing its proprietary Cloudbreak platform. This platform is designed to create conjugates for the prevention and treatment of a range of viral infections, including influenza, RSV, HIV, and SARS-CoV-2 strains causing COVID-19. Cidara's focus on long-acting therapeutics aims to improve patient outcomes by providing sustained drug exposure and reducing the frequency of dosing, which can enhance adherence and efficacy. The company operates primarily in the United States, focusing on addressing unmet medical needs in infectious disease and oncology.

What Products and Services Does CDTX Offer?

• Develop long-acting anti-infectives for treating and preventing infectious diseases.
• Focus on invasive fungal infections, including candidemia and invasive candidiasis.
• Advance the Cloudbreak platform for viral infections like influenza, RSV, HIV, and COVID-19.
• Discover and commercialize novel therapeutic candidates.
• Target unmet medical needs in infectious disease and oncology.
• Improve patient outcomes through sustained drug exposure and reduced dosing frequency.

How Does CDTX Make Money?

• Develop and patent novel anti-infective therapies.
• Conduct preclinical and clinical trials to demonstrate safety and efficacy.
• Seek regulatory approvals from agencies like the FDA.
• Commercialize approved products through sales and marketing efforts, or via partnerships.
• Generate revenue through product sales, licensing agreements, and collaborations.

What Industry Does CDTX Operate In?

Cidara Therapeutics operates within the biotechnology industry, which is characterized by high levels of innovation and risk. The market for anti-infective therapies is driven by the increasing prevalence of drug-resistant infections and the emergence of new pathogens. The competitive landscape includes established pharmaceutical companies and smaller biotechnology firms focused on developing novel treatments for infectious diseases. Cidara's focus on long-acting anti-infectives and its Cloudbreak platform position it to capitalize on the growing demand for innovative solutions in this space.

Who Are CDTX's Key Customers?

• Hospitals and healthcare facilities treating patients with severe fungal infections.
• Patients at risk of or suffering from invasive fungal infections.
• Pharmaceutical companies seeking to license or acquire novel anti-infective therapies.
• Government agencies and public health organizations focused on infectious disease control.

Cidara Therapeutics, Inc. (CDTX) Valuation Context

Valued at $5.61B, CDTX is classified as a mid-cap stock. Analyst price targets span from $150.00 to $221.50, with a consensus of $177.88. At the current price of $221.38, that implies roughly 20% downside from the consensus target.

CDTX Revenue & Earnings Trend

In Sep 2025, CDTX generated $0 in top-line revenue. The company recorded a net loss of $83.2M, with diluted EPS of $-5.35. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, CDTX averaged $-3.51 in diluted EPS.

Company Profile

Cidara Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Jeffrey L. Stein. CDTX has traded publicly since 2015.

Return on equity for Cidara Therapeutics, Inc. stands at -60.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.62 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.4%, the inverse of the P/E and a quick read on earnings relative to price.

Cidara Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 32.61 places it in the safe zone, indicating low near-term bankruptcy risk.

Cidara Therapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 431.9% below estimates on average.

Wall Street analysts project Cidara Therapeutics, Inc. revenue of about $8.4M for fiscal 2026, with EPS near $-6.24. The estimate reflects 4 contributing analysts.

The most recent 12 insider filings for Cidara Therapeutics, Inc. break down as 11 sales and 1 purchases. On net that is roughly 4.8M shares disposed (about $1.0B), a signal worth weighing alongside the fundamentals.

CDTX Financials

CDTX Latest News

What Investors Ask About Cidara Therapeutics, Inc. (CDTX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources